Nanopath
Nanopath is dedicated to developing innovative diagnostic technologies to improve women's health globally. They focus on creating a first-in-class molecular diagnostic platform for scalable, point-of-care disease diagnosis, especially targeting pelvic and gynecologic infections. Their mission is to impact human health through interdisciplinary science and engineering, reimagining diagnostic workflows to provide lab-quality results at the point of care, and addressing complex biological needs of women.
Industries
Nr. of Employees
small (1-50)
Products
Cartridge-and-reader point-of-care diagnostic system
A diagnostic system composed of single-use assay cartridges and a reader device designed to perform multiplexed molecular and biosensor-based tests at the point-of-patient, delivering rapid, lab-quality results.
Cartridge-and-reader point-of-care diagnostic system
A diagnostic system composed of single-use assay cartridges and a reader device designed to perform multiplexed molecular and biosensor-based tests at the point-of-patient, delivering rapid, lab-quality results.
Services
Development of molecular and biosensor-based assays targeting pelvic/gynecologic infections, urinary tract infections, HPV, vaginitis, and STIs for integration into point-of-care platforms.
Engagement in commercial and development partnerships to expand reach and translate diagnostic technologies into clinical and global settings.
Development of molecular and biosensor-based assays targeting pelvic/gynecologic infections, urinary tract infections, HPV, vaginitis, and STIs for integration into point-of-care platforms.
Engagement in commercial and development partnerships to expand reach and translate diagnostic technologies into clinical and global settings.
Expertise Areas
- Point-of-care diagnostics development
- Assay development for infectious diseases
- Biosensor engineering
- Nanotechnology for diagnostics
Key Technologies
- Nanotechnology-based biosensing
- Optical biosensing
- Amplification-free molecular detection
- Multiplexed pathogen detection
News & Updates
Nanopath received a $3 million SBIR grant to develop tests for pelvic and gynecologic infections.
Nanopath was awarded $4 million in grants from the National Institutes of Health and the National Science Foundation.
Nanopath raised $10 million in Series A funding to develop and commercialize point-of-care diagnostics for women's health.
Nanopath was named a semifinalist for the AACC Disruptive Technology Award, recognizing innovative diagnostic solutions.
Nanopath was awarded the Citizen’s Bank Community Champion Award for its community impact.
Nanopath has developed a biosensing platform for women's health diagnostics, providing rapid results without nucleic acid amplification.
Nanopath received a $3 million SBIR grant to develop tests for pelvic and gynecologic infections.
Nanopath was awarded $4 million in grants from the National Institutes of Health and the National Science Foundation.
Nanopath raised $10 million in Series A funding to develop and commercialize point-of-care diagnostics for women's health.
Nanopath was named a semifinalist for the AACC Disruptive Technology Award, recognizing innovative diagnostic solutions.
Nanopath was awarded the Citizen’s Bank Community Champion Award for its community impact.
Nanopath has developed a biosensing platform for women's health diagnostics, providing rapid results without nucleic acid amplification.